Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Bovelli, D ^a   Plataniotis, G ^b   Roila, F ^a  

^a S MARIA HOSPITAL   (Italy)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BLEOMYCIN; BUSULFAN; CAPECITABINE; CISPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; IMATINIB; LAPATINIB; METHOTREXATE; MITOXANTRONE; PACLITAXEL; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; TROPONIN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ARTICLE; AUTONOMIC NEUROPATHY; BRADYCARDIA; BREAST CANCER; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART TAMPONADE; HUMAN; HYPERTENSION; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; LINEAR ACCELERATOR; LUNG FIBROSIS; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PERICARDITIS; PRIORITY JOURNAL; QT PROLONGATION; RAYNAUD PHENOMENON; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TORSADE DES POINTES; VALVULAR HEART DISEASE;

EID: 77954334731     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq200     Document Type: Article

References (58)

1. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 2007; 25: 4952-4960.
2. Jurcut R, Wildiers H, Ganame J et al. Detection and monitoring of cardiotoxicity what does modern cardiology offer? Support Care Cancer 2008; 16: 437-445.
3. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-905.
4. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4: 235-242.
5. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention Drug Saf 2000; 22: 263-302.
6. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25(4 Suppl 10): 72-85.
7. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94: 525-533.
8. Ye ET, Bickford CL. Cardiovascular complications of cancer therapy JACC 2009; 53: 2231-2247.
9. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
10. Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.
11. Yeh ET, Tong AT, Lenihan DJ et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis and management. Circulation 2004; 109: 3122-3131.
12. Raschi E, Vasina V, Ursino MG et al. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 2010; 125: 196-218.
13. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
14. Di Lorenzo G, Autorino R, Bruni G et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multi center analysis. Ann Oncol 2009; 20: 1535-1542.
15. Schmidinger M, Zielinski CC, Vogl UM. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 32: 5204-5211.
16. Seidman AD, Berry D, Cirrincione C et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26: 1642-1649.
17. Altena R, Perik PJ, van Veldhuisen DJ et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009; 10: 391-399.
18. Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist 2008; 13: 1224-1234.
19. Nagy AC, Cserép Z, Tolnay E et al. Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study. Pathol Oncol Res 2008; 14: 69-77.
20. Tassan-Mangina S, Codorean D, Metivier M et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006; 7: 141-146.
21. Sandri MT, Salvatici M, Cardinale D et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005; 58: 1405-1410.
22. Mackey JR, Clemons M, Côté MA et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008; 15: 24-35.
23. Benvenuto GM, Ometto R, Fontanelli A et al. Chemotherapy-realted cardiotoxicity: new diagnostic and preventive strategies. Ital Heart J 2003; 4: 655-667.
24. Levine MN. Trastuzumab cardiac side effects: only time will tell. J Clin Oncol 2005; 23: 7775-7776.
25. Cheitlin MD, Armstrong WF, Aurigemma GP et al. ACC/AHA/ASE 2003 Guideline update for the clinical application of echocardiography. Circulation 2003; 108: 1146-1162.
26. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-1600.
27. Silber JH, Cnaan A, Clark BJ et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22: 820-828.
28. Adams MJ, Hardenbergh PH, Constine LS et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003; 45: 55-75.
29. Adams MJ, Lipshultz SE, Schwartz C et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 2003; 13: 346-356.
30. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106.
31. Hojris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemiac heart disease 3083 high-risk breast cancer patients given adjuvant systemic therapy treatment with or without postmastectomy irradiation: analysis of DBCG 82b and 82c randomised trials. Lancet 1999; 354: 1425-1430.
32. Rutqvist LE, Johanson H. Mortality by laterality of the primary tumor among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990; 61: 866-868.
33. Darby S, McGale P, Peto R et al. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90,000 Swedish women. BMJ 2003; 326: 256-257.
34. Paszat L, Mackillop WJ, Groome PA et al. Mortality from myocardial infraction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology and end-results cancer registries. J Clin Oncol 1998; 16: 2625-2631.
35. Darby SC, McGale P, Taylor CW et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557-565.
36. Giordano SH, Kuo YF, Freeman JL et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005; 97: 419-424.
37. Brosius FC, Waller BF, Roberts WC. Radiation heart disease: analysis of 16 young (aged 15-33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981; 70: 519-530.
38. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment for Hodgkin's disease. JAMA 1993; 270: 1949-1955.
39. Lipshultz SE, Sallan SE. Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 1993; 11: 1199-1203.
40. Stewart JR, Fajardo LF, Gillette SM et al. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995; 31: 1205-1211.
41. Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys. 48. 2000; 169-179.
42. Boivin JF, Hutchison G, Lubin J et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992; 69: 1241-1247.
43. Piovaccari G, Ferretti RM, Prati F et al. Cardiac disease after chest irradiation for Hodgkin's disease: incidence in 108 patients with long follow up. Int J Cardiol 1995; 49: 39-43.
44. Adams JM, Lipsitz SR, Colan SD et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-3148.
45. Glanzmann C, Kaufmann P, Jenni R et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1998; 46: 51-62.
46. Kreuser ED, Voller H, Behles C et al. Evaluation of late cardiotoxicity with pulsed Doppler echocardiography in patients treated for Hodgkin's disease. Br J Haematol 1993; 84: 615-622.
47. Gustavsson A, Eskilsson J, Landberg T et al. Late cardiac effects after mantle radiation in patients with Hodgkin's disease. Ann Oncol 1990; 1: 355-363.
48. Lund MB, Ihlen H, Voss BM et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. Heart 1996; 75: 591-595.
49. Carlson RG, Mayfield W, Normann S et al. Radiation-associated valvular disease. Chest 1991; 99: 538-545.
50. Ramaekers D, Ector H, Aubert AE et al. Heart rate variability and heart rate in healthy volunteers: Is the female autonomic system cardioprotective? Eur Heart J 1998; 19: 1334-1341.
51. Heidenreich PA, Hancock SL, Lee BK et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003; 42: 743-749.
52. Heidenreich PA, Hancock SL, Vagelos RH et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005; 150: 977-982.
53. Swerdlow AJ, Higgins CD, Smith P et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a Collaborative British Cohort Study. J Natl Cancer Inst 2007; 99: 206-214.
54. Taylor CW, McGale P, Darby SC. Cardiac risks of breast-cancer radiotherapy: a contemporary review. Clin Oncol 2006; 18: 236-246.
55. Demirci S, Nam J, Hubbs JL et al. Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. Int J Radiat Oncol Biol Phys 2009; 73: 980-987.
56. Nixon AJ, Manola J, Gelman R et al. No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol 1998; 16: 1374-1379.
57. Landau D, Adams EJ, Webb S, Ross G. Cardiac avoidance in breast radiotherapy: a comparison of simple shielding techniques with intensity-modulated radiotherapy. Radiother Oncol 2001; 60: 247-255.
58. Taylor CW, McGale P, Povall JM et al. Estimating cardiac exposure from breast cancer radiotherapy in clinical practice. Int J Radiat Oncol Biol Phys 2009; 73: 1061-1068.